C9090 – Injection, plasminogen, human-tvmh, 1 mg
HCPCS Level II code · C codes: Outpatient PPS (Hospital Outpatient)
HCPCS codeC9090
- Long description
- Injection, plasminogen, human-tvmh, 1 mg
- Short description
- Plasminogen, human-tvmh 1 mg
- Pricing indicator
53Statute- Medicare coverage
DSpecial coverage instructions apply- BETOS category
O1EOther drugs- Added
- April 1, 2022
- Last change
- July 1, 2022 – No change
- Termination date
- June 30, 2022
Frequently asked questions
What is HCPCS code C9090?
C9090 is a HCPCS Level II code for injection, plasminogen, human-tvmh, 1 mg. It was discontinued on June 30, 2022.
Does Medicare cover C9090?
The HCPCS file lists coverage code D: Special coverage instructions apply. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby C codes
- C9082 – Injection, dostarlimab-gxly, 100 mg
- C9083 – Injection, amivantamab-vmjw, 10 mg
- C9084 – Injection, loncastuximab tesirine-lpyl, 0.1 mg
- C9085 – Injection, avalglucosidase alfa-ngpt, 4 mg
- C9086 – Injection, anifrolumab-fnia, 1 mg
- C9087 – Injection, cyclophosphamide, (auromedics), 10 mg
- C9088 – Instillation, bupivacaine and meloxicam, 1 mg/0.03 mg
- C9089 – Bupivacaine, collagen-matrix implant, 1 mg
- C9091 – Injection, sirolimus protein-bound particles, 1 mg
- C9092 – Injection, triamcinolone acetonide, suprachoroidal (xipere), 1 mg
- C9093 – Injection, ranibizumab, via sustained release intravitreal implant (susvimo), 0.1 mg
- C9094 – Inj, sutimlimab-jome, 10 mg
- C9095 – Inj, tebentafusp-tebn, 1 mcg
- C9096 – Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram
- C9097 – Inj, faricimab-svoa, 0.1 mg
- C9098 – Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.